Annals of Hematology

, Volume 98, Issue 3, pp 605–614 | Cite as

Retrospective evaluation of bone marrow cell morphology in a cohort of patients with isolated idic(20q-) karyotypic abnormalities

  • Dandan Liu
  • Jinlan Pan
  • Chunxiao Wu
  • Jianying Liang
  • Jingjing Wang
  • Suning Chen
  • Zixing ChenEmail author
Original Article


Isochromosome 20q- (i(20q-)), as a rare reproducible chromosomal anomaly formed on the basis of 20q-, has not been commonly reported. Due to the rarity of this karyotypic anomaly, the bone marrow morphological characteristics of the patients with i(20q-) have not been clarified until now. In this study, the bone marrow cell morphology from MDS patients with isolated i(20q-), isolated 20q-, and normal karyotype was retrospectively compared and statistically analyzed. The results indicated that the isolated i(20q-) was mostly detected in MDS-MLD patients. The frequency and proportion dysplasia of cytoplasmic vacuolization in erythoid cells and small or unusually large size in myeloid cells of isolated i(20q-) MDS patients were significantly higher than those of normal karyotype MDS patients respectively (P < 0.05); the frequency and proportion dysplasia of decreased granules/agranularity in myeloid cells of isolated i(20q-) MDS patients were higher than those of isolated 20q- MDS patients (P < 0.05). The incidence of some specific morphological manifestations, such as deeply lobulated and hyperlobulated megakaryocytes and hypogranular and vacuolized eosinophils, may be an important morphological implication for the anomaly of isolated i(20q-). These morphological features of dysplasia may be helpful in distinguishing MDS with isolated i(20q-) from those with isolated 20q- and normal karyotype.


Isolated i(20q-) Isolated 20q- Myelodysplastic syndrome Morphological dysplasia 


Author contributions

Dandan Liu, Jinlan Pan, and Chunxiao Wu contributed equally to this paper.

Funding information

This work was supported in part by the Youth National Natural Science Foundation of China (grant number 81100332) and the Natural Science Foundation of Jiangsu Province (grant number BK20151231).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interests.


  1. 1.
    Asimakopoulos FA, Green AR (1996) Deletions of chromosome 20q and the pathogenesis of myeloproliferative disorders. Br J Haematol 95:219–226CrossRefGoogle Scholar
  2. 2.
    Mitelman F (1991) Catalog of chromosome aberrations in cancer. New YorkGoogle Scholar
  3. 3.
    Li T, Xue Y, Wu Y, Pan J (2004) Clinical and molecular cytogenetic studies in seven patients with myeloid diseases characterized by i(20q-). Br J Haematol 125:337–342CrossRefGoogle Scholar
  4. 4.
    Shetty S, Roland B (2008) Isoderivative chromosome 20 in bone marrow: three new cases. Cancer Genet Cytogenet 184:72–73CrossRefGoogle Scholar
  5. 5.
    Hasserjian RP, Baumann I, Orazi A et al (2017) Myelodysplastic syndromes: overview. In: Swerdlow SH, Campo E, Harris NL et al (ed) WHO classification of tumours of haematopoietic and lymphoid tissues, revised 4th edn. Lyon, France, pp 98–106Google Scholar
  6. 6.
    Shaffer LG, McGowan-Jordan J, Schmid M (2013) ISCN 2013: an international system for human cytogenetics nomenclature. Karger, BaselGoogle Scholar
  7. 7.
    Liu D, Chen Z, Xue Y, Lu D, Zhou Y, Gong J, Wu W, Liang J, Ma Q, Pan J, Wu Y, Wang Y, Zhang J, Shen J (2009) The significance of bone marrow cell morphology and its correlation with cytogenetic features in the diagnosis of MDS-RA patients. Leuk Res 33:1029–1038CrossRefGoogle Scholar
  8. 8.
    Cantù Rajnoldi A, Fenu S, Kerndrup G et al (2005) Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS). Ann Hematol 84:429–433CrossRefGoogle Scholar
  9. 9.
    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405CrossRefGoogle Scholar
  10. 10.
    Mullier F, Daliphard S, Garand R, Dekeyser M, Cornet Y, Luquet I, Talmant P, Richebourg S, Jamar M, Dogné JM, Chatelain C, Michaux L, Chatelain B (2012) Morphology, cytogenetics, and survival in myelodysplasia with del(20q) or i(20q-): a multicenter study. Ann Hematol 91:203–213CrossRefGoogle Scholar
  11. 11.
    Mermel CH, McLemore ML, Liu FL et al (2006) Src family kinases are important negative regulators of G-CSF-dependent granulopoiesis. Blood 108:2562–2568CrossRefGoogle Scholar
  12. 12.
    Moretti S, Lanza F, Spisani S, Latorraca A, Rigolin GM, Giuliani AL, Castoldi GL, Traniello S (1994) Neutrophils from patients with myelodysplastic syndromes: relationship between impairment of granular contents, complement receptors, functional activities and disease status. Leuk Lymphoma 13:471–477CrossRefGoogle Scholar
  13. 13.
    Li T, Xue Y, Wu Y et al (2004) Clinical and cytogenetic features of the myeloid hematological disease with isochromosome 20q. Med J China 84:732–735Google Scholar
  14. 14.
    Ohsaka A, Saionji K, Igari J et al (1997) Altered surface expression of effector cell molecules on neutrophils in myelodysplastic syndromes. Br J Haematol 98:108–113CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Dandan Liu
    • 1
  • Jinlan Pan
    • 1
  • Chunxiao Wu
    • 1
  • Jianying Liang
    • 1
  • Jingjing Wang
    • 1
  • Suning Chen
    • 1
  • Zixing Chen
    • 1
    Email author
  1. 1.The First Affiliated Hospital of Soochow UniversityJiangsu Institute of HematologySuzhouPeople’s Republic of China

Personalised recommendations